The Biostatistics Core provides statistical collaboration and/or data management for each of the SPORE projects, developmental projects, and cores. Each project in this application reflects input from members of the Biostatistics Core on study design and analysis plans. Statistical collaboration and analysis will involve many different fields, including epidemiologic studies, basic sciences, and clinical trials. These studies will be conducted across different platforms with different data management needs, from in vitro experiments to in vivo murine models to phase I/II cancer clinical trials. The Biostatistics Core will provide each investigator access to statistical expertise that includes collaborative development of study designs, data collection tools, analysis plans, state of the art statistical modeling, analysis and interpretation of complex data, data management resources, and abstract and manuscript preparation. The core will also provide statistical collaboration and resources for the developmental projects as well as for pilot projects initiated through the career development component of this grant. In this sense, the Biostatistics Core not only collaborates on and supports the projects presented in this grant application but also will serve as a resource for future investigators interested in participating through this SPORE. In addition to providing statistical collaboration on current and future projects, the Biostatistics Core will work closely with the Clinical Research Core and the Xenograft Core to develop data quality control processes and to assist with the development of new databases or to add database functionality. The Biostatistics core will also develop and help manage project-specific databases as well as to perform necessary data quality control checks. The strengths of the Biostatistics Core are our collaboration with each of the projects, our close integration with the Clinical Research Core and Xenograft Core and the diverse experience or our members. The Biostatistics Core builds upon the innovative and time-tested procedures and systems developed by one of the largest statistical groups in the country whose members have collaborated on more than 8,000 clinical and basic science research studies since 1932.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA108961-01
Application #
6844497
Study Section
Special Emphasis Panel (ZCA1-GRB-V (M1))
Project Start
2004-10-01
Project End
2009-02-28
Budget Start
2004-10-01
Budget End
2005-08-31
Support Year
1
Fiscal Year
2004
Total Cost
$167,412
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43
Vaubel, Rachael A; Caron, Alissa A; Yamada, Seiji et al. (2018) Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathol 28:172-182
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:

Showing the most recent 10 out of 254 publications